Validation by RQ-PCR and flow cytometry of γ-defensin1-3 (DEFA1-3) overexpression in relapsed and refractory acute lymphoblastic leukemia

Oncology Reports

Volumn 15, Issue 2, 2006, Pages 341-346

  Te Kronnie, Geertruy ^a   Bicciato, Silvio ^a   Franceschini, Lisa ^a   Accordi, Benedetta ^a   Dellíorto, Marta Campo ^a   Rinaldi, Andrea ^a   Pession, Andrea ^b   Barisone, Elena ^c   Conter, Valentino ^d   Locatelli, Franco ^e   Basso, Giuseppe ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

^d SAN GERARDO HOSPITAL   (Italy)

^e FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

B lineage acute lymphoblastic leukemia; DEFA1 3; Drug resistance; Expression profiling; Microarray; Relapse

Indexed keywords

ANTINEOPLASTIC AGENT; DEFICIENS PROTEIN; MESSENGER RNA; TUMOR MARKER;

ACUTE LYMPHOCYTIC LEUKEMIA; ADOLESCENT; ARTICLE; BIOSYNTHESIS; CHILD; DNA MICROARRAY; DRUG RESISTANCE; FEMALE; FLOW CYTOMETRY; HUMAN; IN SITU HYBRIDIZATION; INFANT; MALE; METABOLISM; PATHOLOGY; PRESCHOOL CHILD; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR RECURRENCE; UPREGULATION; VALIDATION STUDY;

ADOLESCENT; ANTINEOPLASTIC AGENTS; CHILD; CHILD, PRESCHOOL; DEFICIENS PROTEIN; DRUG RESISTANCE, NEOPLASM; FEMALE; FLOW CYTOMETRY; HUMANS; IN SITU HYBRIDIZATION; INFANT; LEUKEMIA, LYMPHOCYTIC, ACUTE; MALE; NEOPLASM RECURRENCE, LOCAL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 33744457715     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Gaynon PS, Qu RP, Chappell RJ, Willoughby ML, Tubergen DG, Steinherz PG and Trigg ME: Survival after relapse in childhood acute lymphoblastic leukemia: impact of site and time to first relapse - the Children's Cancer Group Experience. Cancer 8: 1387-1395, 1998. (Pubitemid 28155403)
2. Conter V, Arico M, Valsecchi MG, Basso G, Biondi A, Madon E, Mandelli F, Paolucci G, Pession A, Rizzarari C, Rondelli R, Zanesco L and Masera G: Long-term results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) acute lymphoblastic leukemia studies, 1982-1995. Leukemia 14: 2196-2204, 2000. (Pubitemid 32042261)
3. Ganz T and Lehrer RI: Antimicrobal peptides of vertebrates. Curr Opin Immunol 10: 41-44, 1998.
4. Yang D, Biragyn A, Kwak LW and Oppenheim JJ: Mammalian defensins in immunity: more than just microbocidal. Trends Immunol 23: 291-296, 2002. (Pubitemid 34628771)
5. Biragyn A, Surenhu M, Yang D, Ruffini PA, Haines BA, Klyushnenkova E, Oppenheim JJ and Kwak LW: Mediators of innate immunity that target immature, but not mature, dendritic cells induce antitumor immunity when genetically fused with non-immunogenetic tumor antigens. J Immunol 167: 6644-6653, 2001. (Pubitemid 33081603)
6. Blomqvist, M, Bergquist J, Westman A, Hakansson K, Hakansson P, Fredman P and Ekman R: Identification of defensins in human lymphocyte nuclei. Eur J Biochem 263: 312-318, 1999. (Pubitemid 29337020)
7. Basso G, Buldini B, De Zen L and Orfao A: New methodologic approaches for immunophenotyping acute leukemias. Haematologica 86: 675-692, 2001. (Pubitemid 32680993)
8. Van Dongen JJ, Macintyre EA, Gabert JA, Delabesse E, Rossi V, Saglio G, Gottardi E, Rambaldi A, Dotti G, Griesinger F, Parreira A, Gameiro P, Diaz MG, Malec M, Langerak AW, San Miguel JF and Biondi A: Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia 13: 1901-1928, 1999.
9. Germano G, Del Giudice L, Palatron S, Giarin E, Cazzaniga G, Biondi A and Basso G: Clonality profile in relapsed precursor-B-ALL children by GeneScan and sequencing analyses. Consequences on minimal residual disease monitoring, Leukemia 17: 1573-1582, 2003. (Pubitemid 36986960)
10. Koistinen P: Human peripheral blood and bone marrow cell separation using density gradient centrifugation on Lymphoprep and Percoll in haematological disease. Scand J Clin Lab Invest 47: 709-714, 1987.
11. Agerberth B, Charo J, Werr J, Olsson B, Idali F, Lindbom L, Kiessling R, Jornvall H, Wigzell H and Gudmundsson GH: The human antimicrobial and chemotactic peptides LL-37 and alpha-defensins are expressed by specific lymphocyte and monocyte populations. Blood 96: 3086-3093, 2000.
12. Fang XM, Shu Q, Chen QX, Book M, Sahl HG, Hoeft A and Stuber F: Differential expression of alpha- and beta-defensins in human peripheral blood. Eur J Clin Invest 33: 82-87, 2003. (Pubitemid 36051296)
13. Bennett L, Palucka AK, Arce E, Cantrell V, Borvak J, Banchereau J and Pascual V: Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 197: 711-723, 2003. (Pubitemid 36350866)
14. Cheok MH, Yang W, Pui CH, Downing JR, Cheng C, Naeve CW, Relling MV and Evans WE: Treatment-specific changes in gene expression discriminate in vivo drug response in human leukemia cells. Nat Genet 34: 85-90, 2003. (Pubitemid 36548796)
15. Muller CA, Markovic-Lipkovski J, Klatt T, Gamper J, Schwarz G, Beck H, Deeg M, Kalbacher H, Widmann S, Wessels JT, Becker V, Muller GA and Flad T: Human alpha-defensins HNPs-1, -2 and -3 in renal cell carcinoma: influences on tumor cell proliferation. Am J Pathol 160: 1311-1324, 2002. (Pubitemid 34411635)
16. Van der Does-van den Berg A, Bartram CR, Basso G, Benoit YC, Biondi A, Debatin KM, Haas OA, Harbott J, Kamps WA and Koller U: Minimal requirements for the diagnosis, classification and evaluation of the treatment of childhood acute lymphoblastic leukemia (ALL) in the 'BFM Family' Cooperative Group. Med Pediatr Oncol 20: 497-505, 1992.